Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00483132|
Recruitment Status : Completed
First Posted : June 6, 2007
Last Update Posted : June 6, 2007
Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.
High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).
|Condition or disease||Intervention/treatment||Phase|
|Leukemia, Lymphocytic, Acute||Drug: interferon alpha 2a||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||232 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III|
|Study Start Date :||September 1994|
|Actual Study Completion Date :||April 2002|
- overall survival [ Time Frame: time to death ]
- Efficacy of study treatments [ Time Frame: time to end of treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483132
|Angers, chu ANGERS, France, 49000|
|Principal Investigator:||Norbert IFRAH, Pr||French Innovative Leukemia Organisation|
|Principal Investigator:||Noël MILPIED||French Innovative Leukemia Organisation|